All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
AML HubGVhD HubLymphoma HubMDS HubMPN HubMultiple Myeloma Hub

How is relapsed/refractory ALL currently managed in Korea? (KR)

During the 2021 Korean Society of Hematology International Conference & 62nd Annual Meeting (ICKSH 2021), the ALL Hub spoke to Joon Ho Moon, Kyungpook National University, Daegu, KR. We asked, How is relapsed/refractory ALL currently managed in Korea? Moon kindly gave his interview in Korean, with the title '한국의 재발성 및 불응성 급성림프구성백혈병의 치료'.

How is relapsed/refractory ALL currently managed in Korea? (KR)

In this video, Moon discusses the available therapy options used in Korea for patients with ALL, including immunotherapy, chemotherapy, and allogeneic transplantation.

 

Share: